Comparative Pharmacology
Head-to-head clinical analysis: SULSOXIN versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSOXIN versus TRYSUL.
SULSOXIN vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic